From lab to clinic: Translating biochemical discoveries into medical innovations
Main Article Content
Keywords
Biochemical discoveries, medical innovations, Translational research, Bench clinic, Therapy development, Diagnostic applications, Clinical implementation, Healthcare transformation.
Abstract
The journey from laboratory bench to clinical bedside represents a pivotal process of transforming biochemical discoveries into tangible medical innovations. This intricate pathway involves bridging the gap between fundamental research and real-world applications, encompassing developing, validating, and implementing novel therapies and diagnostics. This review explores the dynamic landscape of translating biochemical breakthroughs into clinical advancements. We examine the challenges, strategies, and success stories that underpin the transition from lab-based revelations to life-changing medical interventions. By navigating the intricate journey from bench to clinic, we unveil the transformative power of biochemical discoveries in reshaping the healthcare landscape.
References
2. Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. New England Journal of Medicine, 372(9), 793-795.
3. Kola, I., & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery, 3(8), 711-716.
4. Hamburg, M. A., & Collins, F. S. (2010). The path to personalized medicine. New England Journal of Medicine, 363(4), 301-304.
5. Schork, N. J. (2015). Personalized medicine: Time for one-person trials. Nature, 520(7549), 609-611.
6. Lander, E. S. (2011). The initial impact of the sequencing of the human genome. Nature, 470(7333), 187-197.
7. Wald, N. J., & Morris, J. K. (2002). Teleoanalysis: Combining data from different types of study. British Medical Journal, 324(7343), 595-596.
8. DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003). The price of innovation: New estimates of drug development costs. Journal of Health Economics, 22(2), 151-185.
9. Chabner, B. A., & Roberts, T. G. (2005). Timeline: Chemotherapy and the war on cancer. Nature Reviews Cancer, 5(1), 65-72.
10. Leung, W. K., Wu, M. S., Kakugawa, Y., Kim, J. J., Yeoh, K. G., Goh, K. L., ... & Asia Pacific Working Group on Gastric Cancer. (2008). Screening for gastric cancer in Asia: current evidence and practice. The Lancet Oncology, 9(3), 279-287.
11. Langreth, R., & Waldholz, M. (1994). Genentech gets FDA approval for heart drug: the Wall Street Journal, 27(13), A3.
12. Schimmer, A. D., & Dalgleish, A. (2010). Lymphomas and retroviruses: advances in the understanding of pathogenesis and the use of molecular markers. British Journal of Cancer, 103(5), 689-696.
13. Eichler, H. G., Oye, K., Baird, L. G., Abadie, E., Brown, J., Drum, C. L., ... & Tarrant, C. (2012). Adaptive licensing: taking the next step in the evolution of drug approval. Clinical Pharmacology & Therapeutics, 91(3), 426-437.
14. Miller, F. G., & Joffe, S. (2006). Equipoise and the dilemma of randomized clinical trials. New England Journal of Medicine, 355(5), 541-544.
15. Vos, T., Barber, R. M., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bolliger, I., ... & Duan, L. (2015). Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet, 386(9995), 743-800.
16. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., ... & Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine, 344(11), 783-792.
17. Taubes, G. (2007). The public health burden of obesity in the United States. New England Journal of Medicine, 357(4), 370-379.
18. Lichtenstein, A. H., Appel, L. J., Brands, M., Carnethon, M., Daniels, S., Franch, H. A., ... & Sacks, F. M. (2006). Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation, 114(1), 82-96.
19. Butler, M. G., & Manzardo, A. M. (2012). Forster-Dow syndrome is associated with a microdeletion of Xp11. Three near the STS gene. American Journal of Medical Genetics Part A, 158(7), 1755-1761.
20. Khoury, M. J., & Gwinn, M. L. (2005). The emergence of epidemiology in the genomics age. International Journal of Epidemiology, 34(1), 8-14.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.